## AMENDMENTS TO THE CLAIMS

Please cancel claims 2-3, 5-10 and 22-49.

Please amend claims 1, 4, 11-21, and 50-52 and add new claim 53 as shown in the following list of claims.

- 1. (Currently Amended) An i[[I]]solated polynucleotide[[s]] coding for a ferroportin 1 polypeptide comprising mutated in one of the following amino acids:
- -amino acid at position 80 of SEQ ID NO:2, wherein the glycine at position 80 of SEQ ID NO:2 is substituted with a serine.
- -amino acid at position 174 of SEQ ID NO:2,
- amino acid at position 248 of SEQ ID NO:2, as compared to the wild type sequence.
- 2-3. (Canceled).
- 4. (Currently Amended) <u>The isolated p[[P]]</u>olynucleotide according to claim <u>1</u> [[3]] <u>comprising SEQ ID NO:1</u>, wherein nucleotide 238 of SEQ ID NO:1 is <del>characterized in that said polymorphism is a substitution of a G with an</del> A.
- 5-10. (Canceled).
- 11. (Currently Amended) The isolated p[[P]]olynucleotide according to claim 1, wherein said isolated polynucleotide characterized in that it is genomic DNA.
- 12. (Currently Amended) <u>The isolated p[[P]]</u>olynucleotide according to claim 1, <u>wherein</u> said isolated polynucleotide eharacterized in that it is mRNA.
- 13. (Currently Amended) The isolated p[[P]]olynucleotide according to claim 1, wherein said isolated polynucleotide characterized in that it is cDNA.
- 14. (Currently Amended) The isolated p[[P]]olynucleotide coding for a mutated ferroportin 1 according to claim 1, wherein the characterized in that its nucleotide sequence of said isolated polynucleotide is corresponds to SEQ ID NO:3, 5, or 7.

- 15. (Currently Amended) An isolated p[[P]]olynucleotide comprising more than earrying at least 10 consecutive nucleotides derived from any one of sequences SEQ ID NO:3, 5, or 7, and characterized by comprising at least one of polymorphic nucleotides respectively selected from the group consisting of:
- -wherein the isolated polynucleotide comprises polymorphism corresponding to position 238 of SEQ ID NO:3,
- -polymorphism corresponding to position 521 of SEQ ID NO:5, or
- -polymorphism corresponding to position 744 of SEQ ID NO:7.
- 16. (Currently Amended) The isolated p[[P]]olynucleotide according to claim 15 characterized by <u>further</u> comprising at least one of the oligonucleotides corresponding to sequences of SEQ ID NO: 13 or 14. 9-27.
- 17. (Currently Amended) An isolated p[[P]]olynucleotide having a complementary sequence complementary as compared to the polynucleotide according to claim 15.
- 18. (Currently Amended) <u>The isolated p[[P]]</u>olynucleotide according to claim 1 comprising a label. <del>characterized in that it is labelled.</del>
- 19. (Currently Amended) <u>A r[[R]]</u> ecombinant vector <del>characterized by</del> comprising the isolated polynucleotide according to claim 1.
- 20. (Currently Amended) An i[[I]]solated cell characterized in that it is transfected or transformed with the recombinant vector according to claim 19.
- 21. (Currently Amended) A e[[E]]ukaryotic cell, tissue or non-human animal including a transgene, where in such transgene is at least one isolated[[a]] polynucleotide according to claim 1.
- 22-49. (Canceled).

Response to Office Action dated October 28, 2008 Application No. 10/560,157

- 50. (Currently Amended) A k[[K]]it for the non-HFE hereditary Hemochromatosis diagnosis comprising at least one the isolated polynucleotide of the oligonucleotides according to claim 1.
- 51. (Currently Amended) A k[[K]]it for hereditary impaired iron homeostasis diagnosis comprising at least one the isolated of the polynucleotide[[s]] according to claim 1.
- 52. (Currently Amended) A k[[K]]it for detecting a polymorphism selected from the group consisting of: polymorphism of nucleotide corresponding to position 238 of SEQ ID NO: 1, polymorphism of the nucleotide corresponding to position 521 of SEQ ID NO: 1, polymorphism of the nucleotide corresponding to position 744 of SEQ ID NO: 1 characterized by comprising at least one of the oligonucleotides of sequence: SEQ ID NO: 13, or 14, 19 or 20 optionally in combination with TspR1 at least one of the following restriction enzymes: TspR1, Bsml, Pvull.
- 53. (New) The isolated polynucleotide according to claim 15 or 17 comprising between 15 and 50 consecutive nucleotides.